MARKET

COLL

COLL

Collegium Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.89
-0.10
-0.45%
Opening 13:07 05/11 EDT
OPEN
21.50
PREV CLOSE
21.99
HIGH
22.02
LOW
21.27
VOLUME
134.78K
TURNOVER
--
52 WEEK HIGH
26.91
52 WEEK LOW
15.66
MARKET CAP
771.57M
P/E (TTM)
19.40
1D
5D
1M
3M
1Y
5Y
DJ Collegium Pharmaceutical, Inc. CEO Joe Ciaffoni on Q1 2021 Results -- Earnings Call Transcript >COLL
Dow Jones · 2d ago
Collegium Pharmaceutical (COLL) Beats Q1 Earnings and Revenue Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 36.67% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 4d ago
8-K: COLLEGIUM PHARMACEUTICAL, INC
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
Collegium Pharmaceutical EPS beats by $0.11, beats on revenue
Collegium Pharmaceutical (COLL): Q1 GAAP EPS of $0.41 beats by $0.11.Revenue of $87.72M (+14.7% Y/Y) beats by $6.09M.Press Release
Seekingalpha · 4d ago
Collegium Pharmaceutical Q1 EPS $0.41 Beats $0.30 Estimate, Sales $87.72M Beat $81.87M Estimate
Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.30 by 36.67 percent. This is a 4000 percent increase over earnings of $0.01 per share
Benzinga · 4d ago
Collegium Reports Record Quarterly Revenue of $87.7 Million
- Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 -
GlobeNewswire · 4d ago
Collegium Pharmaceutical, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Collegium Pharmaceutical, Inc. (NASDAQ:COLL) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time.
ACCESSWIRE · 4d ago
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of COLL. Analyze the recent business situations of Collegium Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average COLL stock price target is 30.57 with a high estimate of 40.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 226
Institutional Holdings: 39.13M
% Owned: 111.16%
Shares Outstanding: 35.25M
TypeInstitutionsShares
Increased
39
1.31M
New
19
1.57M
Decreased
53
2.12M
Sold Out
22
595.77K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.66%
Pharmaceuticals & Medical Research
-0.33%
Key Executives
Chairman/Director
Michael Heffernan
President/Chief Executive Officer/Director
Joseph Ciaffoni
Chief Financial Officer/Executive Vice President
Paul Brannelly
Executive Vice President/Chief Technology Officer
Alison Fleming
Executive Vice President/General Counsel/Secretary
Shirley Kuhlmann
Executive Vice President
Scott Dreyer
Executive Vice President
Richard Malamut
Lead Director/Independent Director
Gino Santini
Independent Director
Rita Balice-Gordon
Independent Director
Garen Bohlin
Independent Director
John Fallon
Independent Director
John Freund
Independent Director
Gwen Melincoff
Independent Director
Theodore Schroeder
No Data
About COLL
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Webull offers kinds of Collegium Pharmaceutical Inc stock information, including NASDAQ:COLL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COLL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading COLL stock methods without spending real money on the virtual paper trading platform.